Algernon Pharmaceuticals Inc. (AGN.CN)

0.1150 +0.0100 (+9.52%) At close: 09:37AM EDT

Algernon Pharmaceuticals Inc.

601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
Canada
604-398-4175
https://algernonpharmaceuticals.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Christopher J. Moreau	CEO & Director	544.3k	N/A	1965
Mr. James F. Kinley C.A., CPA	Chief Financial Officer	290.1k	N/A	1978
Dr. Christopher Bryan Ph.D.	Vice President of Research & Operations	300.1k	N/A	1983

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Corporate Governance

Algernon Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.